| Dr Kaydee Willcox Laird, OD | |
|
700 7th St S, Clanton, AL 35045-3778 | |
| (205) 280-0034 | |
| (205) 664-1578 |
| Full Name | Dr Kaydee Willcox Laird |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 4 Years |
| Location | 700 7th St S, Clanton, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619588068 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | S-E55-TA-C04 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vision Hub Llc | 7214330786 | 5 |
| Freeport Vision Center Llc | 8426441924 | 4 |
News Archive
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.
Researchers at the Human Microbiology Institute and Tetz Laboratories have discovered thousands of prion-like domains in human viruses, prompting research that opens new ways of viral pathogenicity, suggests new targets for development of new antiviral drugs and links viruses to diseases such as Alzheimer's and Parkinson's.
Medical Properties Trust, Inc. and MPT Operating Partnership, L.P. today announced the expiration and final results of the previously announced cash tender offer to purchase any and all of the outstanding 9.25% Exchangeable Senior Notes due 2013 (CUSIP Number 55342NAG5) issued by the Operating Partnership at a purchase price of $1,185.29 for each $1,000 principal amount of the exchangeable notes purchased pursuant to the tender offer, plus accrued and unpaid interest to, but not including, the date of payment.
Enzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma.
› Verified 9 days ago
| Provider Name | Vision Hub Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1720652316 PECOS PAC ID: 7214330786 Enrollment ID: O20210721000985 |
News Archive
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.
Researchers at the Human Microbiology Institute and Tetz Laboratories have discovered thousands of prion-like domains in human viruses, prompting research that opens new ways of viral pathogenicity, suggests new targets for development of new antiviral drugs and links viruses to diseases such as Alzheimer's and Parkinson's.
Medical Properties Trust, Inc. and MPT Operating Partnership, L.P. today announced the expiration and final results of the previously announced cash tender offer to purchase any and all of the outstanding 9.25% Exchangeable Senior Notes due 2013 (CUSIP Number 55342NAG5) issued by the Operating Partnership at a purchase price of $1,185.29 for each $1,000 principal amount of the exchangeable notes purchased pursuant to the tender offer, plus accrued and unpaid interest to, but not including, the date of payment.
Enzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma.
› Verified 9 days ago
| Provider Name | Freeport Vision Center Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1417625310 PECOS PAC ID: 8426441924 Enrollment ID: O20220204001565 |
News Archive
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.
Researchers at the Human Microbiology Institute and Tetz Laboratories have discovered thousands of prion-like domains in human viruses, prompting research that opens new ways of viral pathogenicity, suggests new targets for development of new antiviral drugs and links viruses to diseases such as Alzheimer's and Parkinson's.
Medical Properties Trust, Inc. and MPT Operating Partnership, L.P. today announced the expiration and final results of the previously announced cash tender offer to purchase any and all of the outstanding 9.25% Exchangeable Senior Notes due 2013 (CUSIP Number 55342NAG5) issued by the Operating Partnership at a purchase price of $1,185.29 for each $1,000 principal amount of the exchangeable notes purchased pursuant to the tender offer, plus accrued and unpaid interest to, but not including, the date of payment.
Enzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma.
› Verified 9 days ago
| Provider Name | Fort Walton Beach Vision Center Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1225706112 PECOS PAC ID: 5991190407 Enrollment ID: O20220321000973 |
News Archive
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.
Researchers at the Human Microbiology Institute and Tetz Laboratories have discovered thousands of prion-like domains in human viruses, prompting research that opens new ways of viral pathogenicity, suggests new targets for development of new antiviral drugs and links viruses to diseases such as Alzheimer's and Parkinson's.
Medical Properties Trust, Inc. and MPT Operating Partnership, L.P. today announced the expiration and final results of the previously announced cash tender offer to purchase any and all of the outstanding 9.25% Exchangeable Senior Notes due 2013 (CUSIP Number 55342NAG5) issued by the Operating Partnership at a purchase price of $1,185.29 for each $1,000 principal amount of the exchangeable notes purchased pursuant to the tender offer, plus accrued and unpaid interest to, but not including, the date of payment.
Enzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kaydee Willcox Laird, OD 1950 Old Gallows Rd Ste 520, Vienna, VA 22182-3970 Ph: (703) 847-8899 | Dr Kaydee Willcox Laird, OD 700 7th St S, Clanton, AL 35045-3778 Ph: (205) 280-0034 |
News Archive
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.
Researchers at the Human Microbiology Institute and Tetz Laboratories have discovered thousands of prion-like domains in human viruses, prompting research that opens new ways of viral pathogenicity, suggests new targets for development of new antiviral drugs and links viruses to diseases such as Alzheimer's and Parkinson's.
Medical Properties Trust, Inc. and MPT Operating Partnership, L.P. today announced the expiration and final results of the previously announced cash tender offer to purchase any and all of the outstanding 9.25% Exchangeable Senior Notes due 2013 (CUSIP Number 55342NAG5) issued by the Operating Partnership at a purchase price of $1,185.29 for each $1,000 principal amount of the exchangeable notes purchased pursuant to the tender offer, plus accrued and unpaid interest to, but not including, the date of payment.
Enzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma.
› Verified 9 days ago
20 20 Eyecare Inc Optometrist Medicare: Medicare Enrolled Practice Location: 638 Clanton Market Place, Clanton, AL 35045 Phone: 205-755-3636 Fax: 205-755-3777 | |
Betsy Stevenson Farris, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1100 Lay Dam Rd, Clanton, AL 35045 Phone: 205-755-1351 Fax: 205-755-0351 | |
Eye Care Associates, Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1100 Lay Dam Rd, Clanton, AL 35045 Phone: 636-200-4393 Fax: 205-755-0351 | |
Dr. Bethany Baker Lyn, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1100 Lay Dam Rd, Clanton, AL 35045 Phone: 205-755-1351 Fax: 205-755-0351 | |
Bonnie E Mallard, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1415 7th St S, Clanton, AL 35045 Phone: 205-755-7114 Fax: 205-755-8142 | |
Myeyedr Optometrist Medicare: Not Enrolled in Medicare Practice Location: 700 7th St S, Clanton, AL 35045 Phone: 205-280-0034 | |
Advantage Dental Oral Health And Vision Center Of Alabama, P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1141 Jasper Dennis Rd, Clanton, AL 35045 Phone: 205-312-0001 Fax: 205-312-0002 |